
Atomic-level mapping of amorphous diabetes drug reveals hydrogen bonds as key to stability
Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated on a GLP-1 receptor agonist candidate for diabetes and obesity treatment. Their work appears in the Journal of the American Chemical Society.